LRMRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Larimar Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$2.12+0.14 (+6.80%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -39.8% | -95.5% | -132.6% | |
| Return on assets | -36.1% | -77.3% | -95.7% | |
| Current ratio | 13.23 | 10.89 | 2.19 | |
| Debt to equity | – | – | – | |
| Interest coverage | -110.1× | – | – | |
| Diluted shares | 27M | 12M | – |
Where the cash went
Fiscal 2021 to 2025, five years combined
Larimar Therapeutics generated $287.09M from operations and spent $1.20M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$287.09M
Used
$1.20M
Capital expenditure$1.20M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 5 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$165.67M
- Cash generatingOperating cash flow above zero-$113.20M
- Return on assets improvedROA up on the prior year-84.0% → -82.7%
- Earnings backed by cashOperating cash flow above net income-$113.20M vs -$165.67M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose8.02 → 2.19
- No dilutionShare count did not rise61M → –
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –